Molecular formula: C187H291N45O59

Molar Mass: 4113.58

Specification: 5 mg/vial

Purity (HPLC): 99.2%

Semaglutide is a long-acting GLP-1 receptor agonist, developed as a synthetic analog of human glucagon-like peptide-1 (GLP-1), a hormone involved in the regulation of blood sugar levels and appetite. It is a peptide-based therapeutic that mimics natural incretin hormones.

Semaglutide stimulates the secretion of insulin and inhibits the release of glucagon in a glucose-dependent manner. It slows gastric emptying, reduces appetite, and increases satiety, leading to significant weight loss over sustained use. Additionally, it helps normalize blood glucose levels, especially in individuals with type 2 diabetes or metabolic syndrome.

Unlike many weight-loss or antidiabetic drugs, Semaglutide shows minimal risk of hypoglycemia when used alone and has demonstrated cardioprotective effects in clinical trials. Its extended half-life allows for once-weekly injections.

In research and therapeutic settings, Semaglutide is used for:

• Management of type 2 diabetes

• Medical weight loss programs

• Appetite regulation and glucose control

• Obesity treatment in non-diabetic individuals

Suggested Use (Injectable Form):

• Week 1–4: 0.25 mg weekly

• Week 5–8: 0.5 mg weekly

• Week 9+: 1.0 mg weekly or adjusted as needed
  Administered subcutaneously once per week.

Important: Side effects may include nausea, headache, or mild gastrointestinal discomfort, especially during the first weeks of use. Use under medical supervision for optimal safety and effectiveness.

For research purposes only. Not approved for diagnosis, treatment, or prevention of disease.